Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
Open Access
- 7 March 2023
- journal article
- research article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 130, 182-188
Abstract
No abstract availableKeywords
Funding Information
- Norwegian Institute of Public Health (122745)
This publication has 22 references indexed in Scilit:
- Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021Eurosurveillance, 2021
- Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in AdolescentsNew England Journal of Medicine, 2021
- Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021Emerging Infectious Diseases, 2021
- Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort studyThe Lancet, 2021
- Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in AdolescentsNew England Journal of Medicine, 2021
- Covid-19: Keeping schools as safe as possibleBMJ, 2021
- Assessment of 135 794 Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2 Across the United StatesJAMA Pediatrics, 2021
- COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort studyThe Lancet Child & Adolescent Health, 2020
- Estimation of Vaccine Efficacy in Non‐Randomly Mixing PopulationsBiometrical Journal, 1995